Physician profile
Eric S Havens
NPI 1396961025
$1,275.01
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $846 · 2021: $207.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $438.78 | 2019-2020 | |
| Horizon Therapeutics Plc | $372.72 | 2019-2021 | |
| Pfizer INC. | $87.67 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $83.74 | 2019-2020 | |
| Lilly USA, LLC | $57.07 | 2020-2021 | |
| Antares Pharma, INC. | $49.48 | 2019-2020 | |
| Eisai INC. | $47.86 | 2020-2021 | |
| Abbvie INC. | $36.96 | 2019-2021 | |
| Novo Nordisk INC | $31.53 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $20.82 | 2020 | |
| Medtronic, INC. | $20.53 | 2021 | |
| Astellas Pharma US INC | $14.15 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.70 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Havens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.